tbuckley/cabot-search huggingface dataset:
Renal Cortical Perfusion, Measured by Superb Microvascular Imaging, during Infusion of Norepinephrine in Experimental Cardiopulmonary Bypass
Authors: Naoya Iguchi, Yugeesh R. Lankadeva, Roger G. Evans, Andrew D. Cochrane, Bruno Marino, Rinaldo Bellomo, Clive N. May
Journal: American Journal of Respiratory and Critical Care Medicine (2019)
Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma
Authors: Derek A Oldridge, Bao Truong, Douglas Russ, Steven G DuBois, Zalman Vaksman, Yael P Mosse, Sharon J Diskin, John M Maris, Katherine K Matthay
Journal: JNCI Journal of the National Cancer Institute (2019)

Neuroblastoma is a biologically and clinically heterogeneous disease. Based on recent studies demonstrating an association between the primary tumor site, prognosis, and commonly measured tumor biological features, we hypothesized that neuroblastomas arising in different sites would show distinct genomic features reflective of the developmental biology of the sympathicoadrenal nervous system.We first compared genomic and epigenomic data of primary diagnostic neuroblastomas originating in the adrenal gland (n = 646) compared to thoracic sympathetic ganglia (n = 118). We also evaluated association of common germline variation with these primary sites in 1027 European-American neuroblastoma patients.We observed higher rates of MYCN amplification, chromosome 1q gain, and chromosome 11q deletion among adrenal tumors, which were highly predictive of functional RNA signatures. Surprisingly, thoracic neuroblastomas were more likely to harbor ALK driver mutations than adrenal cases among all cases (odds ratio = 1.89, 95% confidence interval = 1.04 to 3.43), and among cases without MYCN amplification (odds ratio = 2.86, 95% confidence interval = 1.48 to 5.49). Common germline single nucleotide polymorphisms (SNPs) in BARD1 (previously associated with high-risk neuroblastoma) were found to be strongly associated with predisposition for origin at adrenal, rather than thoracic, sites.Neuroblastomas arising in the adrenal gland are more likely to harbor structural DNA aberrations including MYCN amplification, whereas thoracic tumors show defects in mitotic checkpoints resulting in hyperdiploidy. Despite the general association of ALK mutations with high-risk disease, thoracic tumors are more likely to harbor gain-of-function ALK aberrations. Site of origin is likely reflective of stage of sympathetic nervous system development when malignant transformation occurs and is a surrogate for underlying tumor biology.
L'endoscopie digestive pratiquée en France en 2005: résultats globaux d'une enquête prospective nationale de la Société Française d'Endoscopie Digestive (SFED)
Authors: JM Canard, JP Arpurt, C Boustière, J Boyer, J Cassigneul, PA Dalbies, J Escourrou, G Gay, R Laugier, JC Letard, B Napoléon, L Palazzo, T Ponchon, B Richard-Molard, D Sautereau, G Tucat, B Vedrenne
Journal: Endoscopy (2007)

Le but de ce travail a été de quantifier prospectivement l'ensemble des endoscopies digestives réalisées en France en 2005 et leur évolution.
TCT-527 Obtainment of Wound Blush is The Most Important Angiographic Endpoint For Wound Healing
Authors: Makoto Utsunomiya, Osamu iida, Yasutaka Yamauchi, Yoshiaki Yokoi, Hiroyoshi Yokoi, Yoshimitsu Soga, Keisuke Hirano, Naoto Inoue, Yusuke Miyashita, Taketsugu Tsuchiya, Toshiro Shinke, Masato Nakamura
Journal: Journal of the American College of Cardiology (2014)
Abstract 17992: Long-Term (10-Year) Mortality of ST Elevation Myocardial Infarction Patients Directly Admitted to Facilities for Primary Percutaneous Coronary Intervention vs Inter-Hospital Transfer: Impact of "Targeted" Use of Pre-Transfer Fibrinolytic Therapy
Authors: Hadi Mahmaljy, Frank V Aguirre, Mohammad Al-akchar, Rohan Kalathiya, Shailesh Nandish, Stephanie A Besser, Varadendra B Panchamukhi, Jenny Chambers, Atman P Shah, James K Liao
Journal: Circulation (2017)

Background: Recent studies have suggested that inherent process delays associated with a universal reperfusion strategy of inter-hospital transfer of ST elevation myocardial infarction (STEMI) patients (pts) for primary PCI (pPCI) may adversely affect clinical outcomes compared to pts directly admitted to a pPCI facility. However, long-term clinical outcomes associated with inter-hospital STEMI reperfusion strategies incorporating pPCI and selective use of pharmacologic reperfusion (FIB) is poorly described. Methods: In this prospective, observational study we define the 10-year mortality among 3,117 consecutive STEMI pts directly admitted (n=1,188; 38%) to 3 pPCI facilities or undergoing inter-hospital transfer (n=1,929; 62%) within an integrated program from 31 rural STEMI-referral hospitals in Central and Southern Illinois between 1/2005 and 12/2014. The inter-hospital transfer STEMI program used a pre-defined reperfusion protocol with emergent transfer for pPCI or use of targeted pre-transfer FIB if...
Patients with autism spectrum disorders display reproducible functional connectivity alterations
Authors: Štefan Holiga, Joerg F. Hipp, Christopher H. Chatham, Pilar Garces, Will Spooren, Xavier Liogier D’Ardhuy, Alessandro Bertolino, Céline Bouquet, Jan K. Buitelaar, Carsten Bours, Annika Rausch, Marianne Oldehinkel, Manuel Bouvard, Anouck Amestoy, Mireille Caralp, Sonia Gueguen, Myriam Ly-Le Moal, Josselin Houenou, Christian F. Beckmann, Eva Loth, Declan Murphy, Tony Charman, Julian Tillmann, Charles Laidi, Richard Delorme, Anita Beggiato, Alexandru Gaman, Isabelle Scheid, Marion Leboyer, Marc-Antoine d’Albis, Jeff Sevigny, Christian Czech, Federico Bolognani, Garry D. Honey, Juergen Dukart
Journal: Science Translational Medicine (2019)

Functional connectivity alterations are conserved in multiple cohorts of patients with autism spectrum disorder.
mTOR inhibition by metformin impacts monosodium urate crystal–induced inflammation and cell death in gout: a prelude to a new add-on therapy?
Authors: Nadia Vazirpanah, Andrea Ottria, Maarten van der Linden, Catharina G K Wichers, Mark Schuiveling, Ellen van Lochem, Amanda Phipps-Green, Tony Merriman, Maili Zimmermann, Matthijs Jansen, Timothy R D J Radstake, Jasper C A Broen
Journal: Annals of the Rheumatic Diseases (2019)

Objective Gout is the most common inflammatory arthritis worldwide, and patients experience a heavy burden of cardiovascular and metabolic diseases. The inflammation is caused by the deposition of monosodium urate (MSU) crystals in tissues, especially in the joints, triggering immune cells to mount an inflammatory reaction. Recently, it was shown that MSU crystals can induce mechanistic target of rapamycin (mTOR) signalling in monocytes encountering these crystals in vitro. The mTOR pathway is strongly implicated in cardiovascular and metabolic disease. We hypothesised that inhibiting this pathway in gout might be a novel avenue of treatment in these patients, targeting both inflammation and comorbidities. Methods We used a translational approach starting from ex vivo to in vitro and back to in vivo. Results We show that ex vivo immune cells from patients with gout exhibit higher expression of the mTOR pathway, which we can mimic in vitro by stimulating healthy immune cells (B lymphocytes, monocytes, T lymphocytes) with MSU crystals. Monocytes are the most prominent mTOR expressers. By using live imaging, we demonstrate that monocytes, on encountering MSU crystals, initiate cell death and release a wide array of proinflammatory cytokines. By inhibiting mTOR signalling with metformin or rapamycin, a reduction of cell death and release of inflammatory mediators was observed. Consistent with this, we show that patients with gout who are treated with the mTOR inhibitor metformin have a lower frequency of gout attacks. Conclusions We propose mTOR inhibition as a novel therapeutic target of interest in gout treatment.
Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT
Authors: Erin Gomez, Phuoc T. Tran, Kenneth J. Pienta, Martin G. Pomper, Michael A. Gorin, Steven P. Rowe
Journal: Clinical Nuclear Medicine (2019)

We present the case of a 71-year-old man with Gleason 3 + 3 = 6 pT2N0MxR0 adenocarcinoma of the prostate who presented with rising PSA level 16 years after radical prostatectomy. PSMA-targeted F-DCFPyL PET/CT was performed, which demonstrated recurrent disease in the prostatectomy bed as well as splenomegaly and mild-diffuse bone marrow activation, consistent with the patient's history of hereditary spherocytosis. We briefly review the clinical characteristics of hereditary spherocytosis, its appearance on molecular imaging studies, the normal biodistribution of F-DCFPyL, and the PSMA-RADS scoring system for characterizing findings on PSMA-targeted PET imaging.
Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy
Authors: Naveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Megan Dupuis, Lisa Zhou, Sherry Pierce, Keyur P. Patel, Lucia Masarova, Jorge Cortes, Srdan Verstovsek
Journal: Blood (2019)
TCT-606 Gender Differences in Fractional Flow Reserve after Percutaneous Coronary Intervention
Authors: Laurens Zandvoort, Roberto Diletti, Miguel Lemmert, Kaneshka Masdjedi, Jeroen Wilschut, Peter de Jaegere, Felix Zijlstra, Nicolas Van Mieghem, Joost Daemen
Journal: Journal of the American College of Cardiology (2018)
Measles: Report of the Medical Officer of Health and School Medical Officer on the Measles Epidemic, 1931-32
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Developing the Next Generation of iPSC Cell-Based Immunotherapies
Authors: Raul Vizcardo, Nicholas Donald Klemen, Rafiqul Islam, Devikala Gurusamy, Naritaka Tamaoki, Li Jia, Zhiya Yu, Amanda N Hennings, Takuya Maeda, Marta Bosch-Marce, Meghan L Good, Svetlana Pack, David F. Stroncek, Francis A Flomerfelt, Michael J Kruhlak, Nicholas Phillip Restifo
Journal: Blood (2018)
Abstract 4818: Type 2 diabetes mellitus and colorectal neoplasia risk in Puerto Rican Hispanics: A case-control study.
Authors: Yaritza Diaz-Algorri, Dilka Gonzalez, Maria E. Lozada, Sofia Margarita Lopez-Diaz, Jessica Hernandez, Carmen Pedrosa, Doris Toro, Marcia R. Criuz-Correa
Journal: Cancer Research (2013)

Abstract Introduction: Epidemiological studies have provided inconclusive evidence regarding the potential link between type 2 diabetes mellitus (DM) and colorectal cancer (CRC).The association between type 2 DM and colorectal neoplasia (colorectal cancer and/or adenomas) has not been well studied in Hispanics, an ethnic minority at high risk for type 2 DM.The specific aim of the study was to evaluate the association between type 2 DM and colorectal neoplasia (CRN) in Puerto Rican Hispanic adults enrolled in the studies Epidemiology of Loss of Imprinting in Colorectal Cancer, Familial Colorectal Cancer Registry and the Type 2 diabetes mellitus and colorectal neoplasia risk in Hispanics: A case-control study at the VA Caribbean Healthcare System. Methods: The case-control study included patients with incident CRN and controls with negative colonoscopy and without previous history of CRC or adenomas diagnosed from January 1, 2005 to December 31, 2009. Diagnosis of type 2 DM was established by previous medical diagnosis and/or anti-diabetic medications use. Unconditional logistic regression was employed to estimate the odds ratio (OR) between type 2 DM and CRN using STATA 10.0. Results: A total of 501 participants (mean age 60.3 ± 12.6 yrs., 57.9% males), prevalence of type 2 DM was 24.8%. 323 patients with CRN and 178 controls were evaluated. In the cases, the prevalence of colorectal adenomas was 25.7% (83/323) and the prevalence of colorectal cancer was 74.3% (240/323). Cases and controls did not differ by gender (p=0.19), median age (p=0.91), family history of CRC (p=0.76) and first degree of family history of DM (p=0.49). Cases had lower education (p&amp;lt;0.001) and reported lower use of NSAIDS (p=0.054) and physical activity (p=0.005) compared to the controls. There were no statistical significant associations between DM and CRN (OR=1.21; 95% CI: 0.79-1.87), DM and CRC (OR=1.20; 95% CI: 0.76-1.90) or DM and colorectal adenomas (OR=1.24; 95% CI: 0.68-2.27). Conclusions: We did not observe a statistical significant association between type 2 DM and CRN. Nonetheless, a tendency towards an increase risk of colorectal neoplasia was observed among type 2 DM patients. Possible explanation for our lack of association may be related to high prevalence of type 2 DM in cases and controls. Citation Format: Yaritza Diaz-Algorri, Dilka Gonzalez, Maria E. Lozada, Sofia Margarita Lopez-Diaz, Jessica Hernandez, Carmen Pedrosa, Doris Toro, Marcia R. Criuz-Correa. Type 2 diabetes mellitus and colorectal neoplasia risk in Puerto Rican Hispanics: A case-control study. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4818. doi:10.1158/1538-7445.AM2013-4818
UCP2-induced fatty acid synthase promotes NLRP3 inflammasome activation during sepsis
Authors: Jong-Seok Moon, Seonmin Lee, Mi-Ae Park, Ilias I. Siempos, Maria Haslip, Patty J. Lee, Mijin Yun, Chun K. Kim, Judie Howrylak, Stefan W. Ryter, Kiichi Nakahira, Augustine M.K. Choi
Journal: Journal of Clinical Investigation (2023)

Cellular lipid metabolism has been linked to immune responses; however, the precise mechanisms by which de novo fatty acid synthesis can regulate inflammatory responses remain unclear. The NLRP3 inflammasome serves as a platform for caspase-1–dependent maturation and secretion of proinflammatory cytokines. Here, we demonstrated that the mitochondrial uncoupling protein-2 (UCP2) regulates NLRP3-mediated caspase-1 activation through the stimulation of lipid synthesis in macrophages. UCP2-deficient mice displayed improved survival in a mouse model of polymicrobial sepsis. Moreover, UCP2 expression was increased in human sepsis. Consistently, UCP2-deficient mice displayed impaired lipid synthesis and decreased production of IL-1β and IL-18 in response to LPS challenge. In macrophages, UCP2 deficiency suppressed NLRP3-mediated caspase-1 activation and NLRP3 expression associated with inhibition of lipid synthesis. In UCP2-deficient macrophages, inhibition of lipid synthesis resulted from the downregulation of fatty acid synthase (FASN), a key regulator of fatty acid synthesis. FASN inhibition by shRNA and treatment with the chemical inhibitors C75 and cerulenin suppressed NLRP3-mediated caspase-1 activation and inhibited NLRP3 and pro–IL-1β gene expression in macrophages. In conclusion, our results suggest that UCP2 regulates the NLRP3 inflammasome by inducing the lipid synthesis pathway in macrophages. These results identify UCP2 as a potential therapeutic target in inflammatory diseases such as sepsis.
Universal antenatal screening for group B streptococcus may cause more harm than good
Authors: Farah Seedat, Julia Geppert, Chris Stinton, Jacoby Patterson, Karoline Freeman, Samantha Ann Johnson, Hannah Fraser, Colin Stewart Brown, Olalekan A Uthman, Bee Tan, Esther R Robinson, Noel Denis McCarthy, Aileen Clarke, John Marshall, Cristina Visintin, Anne Mackie, Sian Taylor-Phillips
Journal: BMJ (2019)

Based on current evidence, routine screening for group B streptococcus colonisation in late pregnancy should not be introduced in the UK, as the potential harms of unnecessary treatment with antibiotics may outweigh the benefits, argue <b>Farah Seedat and colleagues</b>
Risk Factors of Thrombosis in Adults with Primary Immune Thrombocytopenia. a French Nationwide Cohort Study
Authors: Guillaume Moulis, Bérangère Baricault, Charlotta Ekstrand, Margaux Lafaurie, Christian Fynbo Christiansen, Marie Linder, Shahram Bahmanyar, Mette Nørgaard, Laurent Sailler, Maryse Lapeyre-Mestre
Journal: Blood (2018)
Minimising diagnostic delay in lung cancer
Authors: Trevor Keith Rogers
Journal: Thorax (2019)

Lung cancer outcomes have improved only marginally over the last 40 years and remain dismally poor in comparison to most other cancers: only 17.7% of women and 12.9% of men in the UK survive after diagnosis for 5 years or longer.1 This is despite significant investments, with notable recent improvements in diagnostic and staging tools, treatment options and the organisation of teams responsible for streamlined delivery of these. Poor survival is largely attributable to low rates of radically treatable disease at diagnosis. Given that survival rates do vary significantly both within and between countries,2 3 they should be amenable to improvement. How best to do this? Options might include increasing public awareness, improving identification and investigation of putative lung cancer symptoms in primary care, streamlining of secondary care service pathways and screening. All of these have been investigated and they are all of importance.

The finding of a 20% mortality reduction in the National Lung Screening Trial in the USA4 has prompted great interest in low-dose CT (LDCT) screening in high-risk groups. This should be tempered, however, for a number of reasons: only 27% of patients developing lung cancer in the USA would meet the NLST entry criteria, and it is unknown what proportion even of these would attend a screening programme outside a clinical trial; symptomatic presentation particularly of highly malignant forms including small cell lung cancers occurs between screening rounds; screening tends to identify cases of indolent disease (‘overdiagnosis’, estimated to have occurred in up to 18%of the cases in the NLST) as well as cancers with lethal potential ;5 LDCT screening programmes are very costly and only become reasonably cost effective when combined with smoking cessation programmes;6 knowledge regarding appropriate entry criteria, screening protocols and optimal management of lung nodules is still …
Focally Increased Iodine Activity in a Small Thymic Cyst
Authors: Yao Liu, Xia Bai, Da Mu, Jian Wang, Cen Lou
Journal: Clinical Nuclear Medicine (2019)

A 40-year-old man with biopsy-proven papillary thyroid cancer received I radiotherapy. Posttherapy scan showed not only multiple foci of intense activity in the neck but also a small focal activity in the region of right upper mediastinum, confirmed by SPECT/CT images. This activity was suspected as mediastinal lymph node metastasis. However, pathology examination after the resection showed thymic cyst.
Mitigating Health Risks of Prescription Drugs
Authors: Ameet Sarpatwari, Gregory Curfman
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 10361: Prognostic Impact of Sequential Organ Failure Assessment Score in Cardiogenic Shock or Cardiac Arrest Patients With Percutaneous Veno-Arterial Extracorporeal Membrane Oxygenation
Authors: Norihiro Kuroki, Daisuke Abe, Tooru Iwama, Kazuya Tateishi, Masakazu Kaneko, Tomohiko Harunari, Yoshiaki Yui, Takao Yuba, Kou Suzuki, Kazuhiro Sugiyama, Akiko Akashi, Yuichi Hamabe, Akira Sato
Journal: Circulation (2015)

Introduction: Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) has been reported to improve survival in patients with cardiogenic shock or cardiac arrest. However, the prognostic predictors were uncertain. We investigated the association between sequential organ failure assessment (SOFA) score just before implantation and clinical outcome in patients undergoing VA-ECMO due to cardiogenic shock and cardiac arrest. Methods: A cohort of 299 patients who underwent ECMO at our hospital was registered from January 2005 to April 2015. We excluded 72 patients caused by non-cardiogenic event. The remaining 227 patients (58±14 years old, male82%) were divided into 2 groups according to initial sequential organ failure assessment (SOFA) score . High SOFA Group: SOFA score ≥13 points (n=106); Low SOFA Group: SOFA score &lt;13 (n=121). Clinical outcome was all -cause death at 30 days. Results: The 87% of patients received VA-ECMO due to cardiac arrest(81 out-of-hospital cardiac arrest, 116 in-hospital cardiac arrest). In baseline characteristics, Low SOFA group was significantly shorter time from collapse to ECMO (35.1 vs. 40.7 min), higher Hb (13.1 vs. 11.6 g/dl), and lower BUN (18.1 vs. 24.4 mEq/l, all p&lt;0.05) than High SOFA group. Incidence of death at 30days was significantly lower in Low SOFA group than in High SOFA group (Low SOFA vs. High SOFA; 56.2% vs. 76.4%: p= 0.0014) . Kaplan-Meier curve showed Low SOFA group was better outcome compared with High group (p&lt;0.001, log-rank test) (Figure). SOFA score was an independent predictor of mortality after adjustment of multiple cofounders (SOFA Score per increase, OR: 1.18, 95% confidence interval: 1.00-1.39, p=0.047). Positive independent predictors of mortality were age (per increase OR: 1.04, 95% CI: 1.01-1.07, p&lt;0.01) and other factors. Conclusions: Initial high SOFA score just before implantation provides worse clinical outcome in patients with VA-ECMO due to cardiogenic shock and cardiac arrest.